Novel treatment strategies for antibody-mediated diseases: Targeting long-lived plasma cells

Future Rheumatology

Volumn 3, Issue 4, 2008, Pages 311-315

  Voll, Reinhard E ^a,b   Neubert, Kirsten ^a   Meister, Silke ^a   Gückel, Eva ^a   Kalden, Joachim R ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATACICEPT; AUTOANTIBODY; AZATHIOPRINE; BELIMUMAB; BISPECIFIC ANTIBODY; BORTEZOMIB; CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE STRANDED DNA; EPRATUZUMAB; FC RECEPTOR; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG MEGADOSE; EDITORIAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 55649091999     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.4.311     Document Type: Editorial

References (33)

1. Hershko AY, Naparstek Y: Removal of pathogenic autoantibodies by immunoadsorption. Ann. NY Acad. Sci. 1051, 635-646 (2005).
2. Petkova SB, Konstantinov KN, Sproule TJ, Lyons BL, Awwami MA, Roopenian DC: Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc γ RIIB. J. Exp. Med. 203, 275-280 (2006).
3. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM: Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 148, 2103-2108 (1992).
4. Deocharan B, Qing X, Lichauco J, Putterman C: α-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J. Immunol. 168, 3072-3078 (2002).
5. Mostoslavsky G, Fischel R, Yachimovich N et al.: Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur. J. Immunol. 31, 1221-1227 (2001).
6. Smoyer WE, Mundel P, Gupta A, Welsh MJ: Podocyte α-actinin induction precedes foot process effacement in experimental nephrotic syndrome. Am. J. Physiol. 273, F150-F157 (1997).
7. Conti-Fine BM, Milani M, Kaminski HJ: Myasthenia gravis: past, present, and future. J. Clin. Invest. 116, 2843-2854 (2006).
8. Mohan C, Datta SK: Lupus: key pathogenic mechanisms and contributing factors. Clin. Immunol. Immunopathol. 77, 209-220 (1995).
9. Nangaku M, Couser WG: Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin. Exp. Nephrol. 9, 183-191 (2005).
10. Holme PA, Brosstad F, Tjonnfjord GE: Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 11, 510-515 (2005).
11. Ehrenstein MR, Katz DR, Griffiths MH et al.: Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 48, 705-711 (1995).
12. Koren E, Koscec M, Wolfson-Reichlin M et al.: Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. J. Immunol. 154, 4857-4864 (1995).
13. Manz RA, Radbruch A: Plasma cells for a lifetime? Eur. J. Immunol. 32, 923-927 (2002).
14. Miller JJ 3rd, Cole LJ: Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6-mercaptopurine, and actinomycin D. J. Exp. Med. 126, 109-125 (1967).
15. Slifka MK, Ahmed R: Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10, 252-258 (1998).
16. Slifka MK, Antia R, Whitmire JK, Ahmed R: Humoral immunity due to long-lived plasma cells. Immunity 8, 363-372 (1998).
17. Hoyer BF, Moser K, Hauser AE et al.: Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577-1584 (2004).
18. Manz RA, Thiel A, Radbruch A: Lifetime of plasma cells in the bone marrow. Nature 388, 133-134 (1997).
19. Kessel A, Rosner I, Toubi E: Rituximab: beyond simple B cell depletion. Clin. Rev. Allergy Immunol. 34, 74-79 (2008).
20. Cambridge G, Leandro MJ, Teodorescu M et al.: B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54, 3612-3622 (2006).
21. Looney RJ, Anolik JH, Campbell D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004).
22. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, R74 (2006).
23. Schneider P: The role of APRIL and BAFF in lymphocyte activation. Curr. Opin. Immunol. 17, 282-289 (2005).
24. Pers JO, Daridon C, Devauchelle V et al.: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. NY Acad. Sci. 1050, 34-39 (2005).
25. Stohl W, Xu D, Kim KS et al.: BAFF overexprassion and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 52, 2080-2091 (2005).
26. Furie R, Petri M, Weisman MH et al.: Belimumab (fully human monoclonal antibody to BLys) improved or stabilized systemic lupus erythematosus (SLE) disease activity and reduced flare rate during 3 years of therapy. Ann. Rheum. Dis. 67, 53 (2008).
27. Tak PP, Thurlings RM, Rossier C et al.: Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58, 61-72 (2008).
28. Radbruch A, Muehlinghaus G, Luger EO et al.: Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741-750 (2006).
29. Neubert K, Meister S, Moser K et al.: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. (2008).
30. Meister S, Schubert U, Neubert K et al.: Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783-1792 (2007).
31. Cenci S, Mezghrani A, Cascio P et al.: Progressively impaired proteasomal capacity during terminal plasma cell differentiation. Embo. J. 25, 1104-1113 (2006).
32. Cascio P, Oliva L, Cerruti F et al.: Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur. J. Immunol. 38, 658-667 (2008).
33. Tchorbanov AI, Voynova EN, Mihaylova NM et al.: Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 37, 3587-3596 (2007).